Tanning Peptide Melanotan-II Linked to Melanoma Development in Case Study

Melanotan-II (MT-II) is a synthetic melanocortin receptor agonist, primarily targeting MC1R, MC3R, and MC4R, known for its ability to induce skin tanning by increasing melanin production. Despite its cosmetic appeal, MT-II is unregulated in many regions, leading to concerns about its safety and potential long-term health consequences, particularly regarding skin cancer. The most severe form of skin cancer is melanoma, which originates from melanocytes. This study presents a crucial case report detailing a direct association between the recreational use of Melanotan-II and the subsequent diagnosis of malignant melanoma, highlighting significant public health risks.

The patient, a 32-year-old male with no prior history of atypical nevi or melanoma, reported consistent self-administration of Melanotan-II for approximately 18 months. During this period, he observed the rapid appearance of multiple new pigmented lesions and significant changes in existing moles, prompting medical consultation. Clinical examination revealed several dysplastic nevi and one particularly suspicious lesion on the back, measuring approximately 8 mm in diameter. Histopathological examination of the excised lesion confirmed a diagnosis of malignant melanoma, specifically a superficial spreading melanoma with a Breslow thickness of 1.2 mm and a mitotic rate of 2 mitoses/mm². > The most critical finding was the strong temporal correlation between the initiation of Melanotan-II use and the accelerated development of new, atypical nevi, culminating in a histopathologically confirmed malignant melanoma in a previously low-risk individual. This suggests a potential role for MT-II in either promoting melanoma development or accelerating its progression.